Literature DB >> 21546537

Combinatorial effect of probucol and cilostazol in focal ischemic mice with hypercholesterolemia.

Ji Hyun Kim1, Sun Haeng Park, Sun Sik Bae, Ki Whan Hong, Yong Deok Kim, Kyung Pil Park, Byung Tae Choi, Hwa Kyoung Shin.   

Abstract

Hypercholesterolemia may increase stroke risk by accelerating atherosclerosis, narrowing the luminal diameter in cerebral vessels, and disrupting both vascular endothelial and smooth muscle function. In the present study, we investigated the beneficial effects of combinatorial therapy with probucol and cilostazol on focal cerebral ischemia with hypercholesterolemia. Apolipoprotein E (ApoE) knockout (KO) mice were fed a high-fat diet with or without 0.5% probucol and/or 0.2% cilostazol for 10 weeks. Probucol alone and probucol and cilostazol significantly decreased total, low-density lipoprotein, and high-density lipoprotein cholesterol, whereas cilostazol did not affect the plasma cholesterol levels in ApoE KO mice. Administration of probucol alone and cilostazol alone significantly decreased atherosclerotic lesion area in the aorta, with a significant decrease evident using combinatorial administration. Middle cerebral artery occlusion resulted in significantly larger infarct volumes in ApoE KO mice fed 10 weeks of high-fat diet compared with those in ApoE KO mice fed a regular diet. The infarct volume was reduced significantly using probucol alone or cilostazol alone and even was reduced significantly by their combinatorial administration. Consistent with a larger infarct size, the combinatorial therapy prominently improved neurological function. The combinatorial administration increased cerebral blood flow during ischemia. Expression of endothelial nitric oxide synthase and adiponectin in the cortex were decreased by high-fat diet but were elevated by combinatorial treatment. Adiponectin expression colocalized within the cerebral vascular endothelium. The data suggest that the combination of probucol and cilostazol prevents cerebrovascular damage in focal cerebral ischemic mice with hypercholesterolemia by up-regulation of endothelial nitric oxide synthase and adiponectin.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21546537     DOI: 10.1124/jpet.111.181180

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Oral absorption enhancement of probucol by PEGylated G5 PAMAM dendrimer modified nanoliposomes.

Authors:  Qian Ma; Yingchun Han; Cong Chen; Yini Cao; Siling Wang; Wenwen Shen; Huayu Zhang; Yanzhi Li; Mallory A van Dongen; Bing He; Maomao Yu; Lu Xu; Mark M Banaszak Holl; George Liu; Qiang Zhang; Rong Qi
Journal:  Mol Pharm       Date:  2015-01-27       Impact factor: 4.939

2.  Probucol inhibits LPS-induced microglia activation and ameliorates brain ischemic injury in normal and hyperlipidemic mice.

Authors:  Yeon Suk Jung; Jung Hwa Park; Hyunha Kim; So Young Kim; Ji Young Hwang; Ki Whan Hong; Sun Sik Bae; Byung Tae Choi; Sae-Won Lee; Hwa Kyoung Shin
Journal:  Acta Pharmacol Sin       Date:  2016-06-27       Impact factor: 6.150

3.  Early effects of high-fat diet on neurovascular function and focal ischemic brain injury.

Authors:  Weiguo Li; Roshini Prakash; Dhruv Chawla; Wenting Du; Sean P Didion; Jessica A Filosa; Quanguang Zhang; Darrell W Brann; Victor V Lima; Rita C Tostes; Adviye Ergul
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-04-10       Impact factor: 3.619

4.  Multi-target drugs: the trend of drug research and development.

Authors:  Jin-Jian Lu; Wei Pan; Yuan-Jia Hu; Yi-Tao Wang
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

5.  Probucol-Induced α-Tocopherol Deficiency Protects Mice against Malaria Infection.

Authors:  Maria Shirely Herbas; Mototada Shichiri; Noriko Ishida; Aiko Kume; Yoshihisa Hagihara; Yasukazu Yoshida; Hiroshi Suzuki
Journal:  PLoS One       Date:  2015-08-21       Impact factor: 3.240

6.  Probucol plus cilostazol attenuate hypercholesterolemia‑induced exacerbation in ischemic brain injury via anti-inflammatory effects.

Authors:  Ji Hyun Kim; Ki Whan Hong; Sun Sik Bae; Yong-Il Shin; Byung Tae Choi; Hwa Kyoung Shin
Journal:  Int J Mol Med       Date:  2014-07-10       Impact factor: 4.101

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.